IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Modak *et al.*			
Appln. No.	:	10/600,257	Examiner	:	Azpuru, Carlos A.
Filed	:	June 20, 2003	Group Art Unit	:	1615
For	:	ANTIMICROBIAL MEDICAL DEVICES			

LETTER

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
March 24, 2005
Date of Deposit

Peter J. Shen — 52,217
Attorney Name — Patent Reg. No.

Signature — March 24, 2005
Date of Signature

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants enclose herewith copies of all foreign patent documents and literature references listed on the Form PTO-1449, copy enclosed, filed with the Information Disclosure Statement on March 21, 2005 for the referenced application.

Respectfully submitted,

BAKER BOTTS L.L.P.

By: _____
Peter J. Shen
Patent Office Reg. No. 52,217
30 Rockefeller Plaza, 44th Floor
New York, NY 10012-4498
Attorney for Applicants
212-408-2500

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 33432-A-PCT-USA-A (070050.2407)	Serial No. 10/600,257
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	Applicants Modak et al.	
	Filing Date June 20, 2003	Group Art Unit 1615

U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date ifAppropriate
		4 6 0 5 5 6 4	08/12/86	Kulla et al.	427	2.3	
		4 7 2 3 9 5 0	02/09/88	Lee	604	322	
		4 9 9 9 2 1 0	03/12/91	Solomon et al.	427	2	
		4 9 9 4 0 4 7	02/19/91	Walker et al.	604	264	
		5 0 1 3 3 0 6	05/07/91	Solomon et al.	604	265	
		5 0 1 9 0 9 6	05/28/91	Fox, Jr. et al.	600	36	
		5 0 3 3 4 8 8	07/23/91	Curtis et al.	132	321	
		5 0 8 9 2 0 5	02/18/92	Huang et al.	264	255	
		5 0 9 1 4 4 2	02/25/92	Milner	523	122	
		5 1 0 2 4 0 1	04/07/92	Lambert et al.	604	264	
		5 1 6 5 9 5 2	11/24/92	Solomon et al.	427	2.25	
		5 1 8 0 6 0 5	01/19/93	Milner	427	2.3	
		5 2 0 0 1 9 4	04/06/93	Edgren et al.	424	473	
		5 2 0 9 2 5 1	05/11/93	Curtis et al.	132	321	
		5 2 6 1 4 2 1	11/16/93	Milner	128	898	
		5 3 5 7 6 3 6	10/25/94	Dangman et al.	2	161.7	
		5 3 3 5 3 7 3	08/09/94	Dangman et al.	2	161.7	
		5 3 5 7 6 3 6	10/25/94	Dresdner, Jr. et al.	2	161.7	
		5 4 2 0 1 9 7	05/30/95	Lorenz et al.	525	54.3	
		5 4 5 1 4 2 4	09/19/95	Solomon et al.	427	2.1	
		5 6 1 6 3 3 8	04/01/97	Fox Jr. et al.	424	423	
		5 7 0 7 3 6 6	01/13/98	Solomon et al.	604	265	

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 33432-A-PCT-USA-A (070050.2407)	Serial No. 10/600,257
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	Applicants Modak et al.	
	Filing Date June 20, 2003	Group Art Unit 1615

		5	7	7	2	6	4	0	06/30/98	Modak et al.	604	265	
		6	0	8	3	2	0	8	07/04/00	Modak et al.	604	265	
		6	1	0	6	5	0	5	08/22/00	Modak et al.	604	265	
		6	2	2	4	5	7	9	05/01/01	Modak et al.	604	265	
		6	2	6	1	2	7	1	07/17/01	Solomon et al.	604	265	
		6	6	2	6	8	7	3	09/30/03	Modak et al.	604	265	

FOREIGN PATENT DOCUMENT

		Document No.							Date	Country	Class	SubClass	Translator Yes	Translator No
		0	3	2	8	4	2	1	08/16/89	EP				
		0	3	7	9	2	7	1	07/25/90	EP				
		0	4	7	2	4	1	3	08/21/91	EP				
		9	3	0	6	8	8	1	04/15/93	WO				
		9	3	0	2	7	1	7	02/18/93	WO				
		0	6	6	3	2	1	2	05/30/95	EP				
		9	6	2	2	1	1	4	07/25/96	WO				
		9	7	2	5	0	8	5	07/17/97	WO				
	1	1	0	4	9	6	2	5	02/23/99	JP				
		0	0	5	7	9	3	3	10/05/00	WO				

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

			The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Tenth Edition Merck & Co., Inc., Rahway, NJ, 1983, p. 1092.

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 33432-A-PCT-USA-A (070050.2407)	Serial No. 10/600,257
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	Applicants Modak et al.	
	Filing Date June 20, 2003	Group Art Unit 1615

			Bach A, Bohrer H, Motsch J, Martin E, Geiss HK, Sonntag HG. Prevention of bacterial colonization of intravenous catheters by antiseptic impregnation of polyurethane polymers. J Antimicrob Chemother. 1994 May;33(5):969-78.
			Choi L, Choudhri AF, Pillarisetty VG, Sampath LA, Caraos L, Brunnert SR, Oz MC, Modak SM. Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections. J Heart Lung Transplant. 1999 Nov;18(11):1103-10.
			Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother. 2001 May;47(5):589-98.
			Kim CY, Kumar A, Sampath L, Sokol K, Modak S. Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats. Am J Kidney Dis. 2002 Jan;39(1):165-73.
			Gaonkar TA, Sampath LA, Modak SM. Evaluation of the antimicrobial efficacy of urinary catheters impregnated with antiseptics in an in vitro urinary tract model. Infect Control Hosp Epidemiol. 2003 Jul;24(7):506-13.
			On April 17, 2000, which is prior to the December 22, 2000 filing date of the present application (Serial No. 09/746,670), a triple lumen catheter was sold by the licensee, Arrow Incorporated, in the United States. This catheter had an outer coating prepared using a solution containing three percent (3%) weight by volume (w/v) of chlorhexidine diacetate and 0.75 percent w/v silver sulfadiazine. The catheter had an inner lumen coating prepared using a solution containing the solvent ethanol, 0.75 percent (0.75%) w/v chlorhexidine free base, and 0.75 percent (0.75%) w/v chlorhexidine diacetate.

Examiner Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.